- Home
- BEEM vs AKTX Comparison
BEEM vs AKTX Comparison
Compare BEEM & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BEEM
- AKTX
- Stock Information
- Founded
- BEEM 2006
- AKTX N/A
- Country
- BEEM United States
- AKTX United States
- Employees
- BEEM N/A
- AKTX N/A
- Industry
- BEEM Semiconductors
- AKTX Biotechnology: Pharmaceutical Preparations
- Sector
- BEEM Technology
- AKTX Health Care
- Exchange
- BEEM Nasdaq
- AKTX Nasdaq
- Market Cap
- BEEM 35.5M
- AKTX 35.7M
- IPO Year
- BEEM N/A
- AKTX N/A
- Fundamental
- Price
- BEEM $2.35
- AKTX $0.79
- Analyst Decision
- BEEM Strong Buy
- AKTX Strong Buy
- Analyst Count
- BEEM 4
- AKTX 2
- Target Price
- BEEM $5.33
- AKTX $3.30
- AVG Volume (30 Days)
- BEEM 190.8K
- AKTX 91.9K
- Earning Date
- BEEM 11-13-2025
- AKTX 08-13-2025
- Dividend Yield
- BEEM N/A
- AKTX N/A
- EPS Growth
- BEEM N/A
- AKTX N/A
- EPS
- BEEM N/A
- AKTX N/A
- Revenue
- BEEM $33,362,000.00
- AKTX N/A
- Revenue This Year
- BEEM N/A
- AKTX N/A
- Revenue Next Year
- BEEM $45.38
- AKTX N/A
- P/E Ratio
- BEEM N/A
- AKTX N/A
- Revenue Growth
- BEEM N/A
- AKTX N/A
- 52 Week Low
- BEEM $1.33
- AKTX $0.57
- 52 Week High
- BEEM $5.57
- AKTX $3.85
- Technical
- Relative Strength Index (RSI)
- BEEM 44.39
- AKTX 40.50
- Support Level
- BEEM $2.41
- AKTX $0.57
- Resistance Level
- BEEM $2.63
- AKTX $0.89
- Average True Range (ATR)
- BEEM 0.17
- AKTX 0.07
- MACD
- BEEM -0.05
- AKTX 0.01
- Stochastic Oscillator
- BEEM 12.20
- AKTX 60.72
About BEEM Beam Global
Beam Global produces sustainable technology for electric vehicle (EV) charging, outdoor media, and energy security, without the construction, disruption, and costs of grid-tied solutions. Its products are founded upon its patented EV ARC and Solar Treelines and include BeamTrak patented solar tracking, and ARC Technology energy storage, along with EV charging, outdoor media, and disaster preparedness packages. From start to finish, the company develops, patents, designs, engineers, and manufactures renewably energized products that help the environment, empower communities, and keep people moving.
About AKTX Akari Therapeutics plc ADS
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.